Search Results

Altasciences announced today that it has been recognized for excellence in contract research with a 2024 CRO Leadership Award for Capabilities.

Altasciences announced the appointment of James Brazeal as General Manager, Clinical Operations, at its clinical facility in Kansas City.

Hoth Therapeutics, Inc. announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth’s sponsored scientific research conducted at NC State University.

Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.

Altasciences is pleased to have completed a Phase I trial on Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, for the treatment of acute TBI.

Altasciences is pleased to have been chosen by Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) (“Virpax”), a company specializing in developing non-addictive products for pain management, PTSD, central nervous system (CNS) disorders, and viral barrier indications, to conduct preclinical studies in support of their development of quaternary ammonium palmitoyl glycol chitosan (GCPQ, under the trade name of AnQlar™).

Proscia®, a leading provider of digital and computational pathology solutions, today announced that Altasciences, a forward-thinking contract research organization (CRO), has chosen Concentriq® for Research to help its sponsors get life-saving therapeutics to patients sooner.

Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s).

Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.